Warnecke Athanasia, Prenzler Nils K, Schmitt Heike, Daemen Kerstin, Keil Jana, Dursin Martin, Lenarz Thomas, Falk Christine S
Department of Otolaryngology, Hannover Medical School, Hanover, Germany.
Cluster of Excellence of the German Research Foundation (DFG; "Deutsche Forschungsgemeinschaft") "Hearing4all", Oldenburg, Germany.
Front Neurol. 2019 Jun 25;10:665. doi: 10.3389/fneur.2019.00665. eCollection 2019.
The molecular pathomechanisms in the majority of patients suffering from acute or progressive sensorineural hearing loss cannot be determined yet. The size and the complex architecture of the cochlea make biopsy and in-depth histological analyses impossible without severe damage of the organ. Thus, histopathology correlated to inner disease is only possible after death. The establishment of a technique for perilymph sampling during cochlear implantation may enable a liquid biopsy and characterization of the cochlear microenvironment. Inflammatory processes may not only participate in disease onset and progression in the inner ear, but may also control performance of the implant. However, little is known about cytokines and chemokines in the human inner ear as predictive markers for cochlear implant performance. First attempts to use multiplex protein arrays for inflammatory markers were successful for the identification of cytokines, chemokines, and endothelial markers present in the human perilymph. Moreover, unsupervised cluster and principal component analyses were used to group patients by lead cytokines and to correlate certain proteins to clinical data. Endothelial and epithelial factors were detected at higher concentrations than typical pro-inflammatory cytokines such as TNF-a or IL-6. Significant differences in VEGF family members have been observed comparing patients with deafness to patients with residual hearing with significantly reduced VEGF-D levels in patients with deafness. In addition, there is a trend toward higher IGFBP-1 levels in these patients. Hence, endothelial and epithelial factors in combination with cytokines may present robust biomarker candidates and will be investigated in future studies in more detail. Thus, multiplex protein arrays are feasible in very small perilymph samples allowing a qualitative and quantitative analysis of inflammatory markers. More results are required to advance this method for elucidating the development and course of specific inner ear diseases or for perioperative characterization of cochlear implant patients.
大多数急性或进行性感音神经性听力损失患者的分子发病机制尚未明确。耳蜗的大小和复杂结构使得在不严重损害该器官的情况下进行活检和深入的组织学分析成为不可能。因此,与内耳疾病相关的组织病理学仅在死后才有可能实现。在人工耳蜗植入过程中建立一种外淋巴采样技术,可能会实现液体活检并对内耳微环境进行表征。炎症过程不仅可能参与内耳疾病的发生和发展,还可能控制植入物的性能。然而,关于人内耳中的细胞因子和趋化因子作为人工耳蜗性能预测标志物的了解甚少。首次尝试使用多重蛋白质阵列检测炎症标志物,成功鉴定出人外淋巴中存在的细胞因子、趋化因子和内皮标志物。此外,还使用了无监督聚类分析和主成分分析,根据主要细胞因子对患者进行分组,并将某些蛋白质与临床数据相关联。检测到内皮和上皮因子的浓度高于典型的促炎细胞因子,如肿瘤坏死因子-α或白细胞介素-6。与有残余听力的患者相比,耳聋患者的血管内皮生长因子(VEGF)家族成员存在显著差异,耳聋患者的VEGF-D水平显著降低。此外,这些患者的胰岛素样生长因子结合蛋白-1(IGFBP-1)水平有升高趋势。因此,内皮和上皮因子与细胞因子相结合,可能是强有力的生物标志物候选物,将在未来的研究中进行更详细的研究。因此,多重蛋白质阵列在非常少量的外淋巴样本中是可行的,能够对炎症标志物进行定性和定量分析。需要更多的研究结果来推进该方法,以阐明特定内耳疾病的发展和进程,或对人工耳蜗植入患者进行围手术期特征分析。